65,437 trials
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants
Peyronie's Disease
Primary: Change From Baseline in Penile Curvature — -29.7; -11.0 Percent change from baseline — p=0.001
Hypertension
Primary: Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12 — -10.1; -7.3 mmHG
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving BASDAI 40 Response at Week 24 — 83.6 Percentage of participants
Major Depressive Disorder · Partner Relational Disorder (V61.10)
Primary: Hamilton Depression Rating Scale (HDRS) — 17.86; 19.0; 5.00; 7.29 Score on HDRS — p=0.056
Peripheral Vascular Diseases · Thrombosis · Venous Thrombosis
Primary: Change From Baseline to Final Angiographic Results — 1.32; 1.37; 1.16; 1.89 Occlusion Index — p=<0.0001
Tonsillitis
Primary: Time to First Morphine Dose — 19; 43.7; 61.1; 137.6 minutes
Diabetes Mellitus, Type 2
Primary: Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population…
Otitis
Primary: Incidence of Pain — 6; 11; 7; 18 participants
HIV Infections
Primary: New or Recurrent HIV Disease Progression Event Including Death — 159; 165 participants — p=.55
Myeloma
Primary: Number of Patients Reaching Complete Response (CR) — 4; 1; 4 participants
Anterior Ischemic Optic Neuropathy · Ischemic Optic Neuropathy
Primary: Crude Incidence Rate of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Per 1000 Person-years by Age — 0.01; 0.01; 0.03; 0.12 incidence rate per 1000 person-years
Gastroesophageal Reflux Disease · Heartburn · Regurgitation
Primary: Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment…
Cocaine Dependence · Depressive Symptoms
Primary: Urine Toxicology Screens for the Presence of Cocaine/Cocaine Metabolites — 19.93; 23.38; 17.27 Days to relapse (two consec coc+ urines) — p=0.05
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis 2 Acid Maltase Deficiency
Primary: Participants' Efficacy Response During the Treatment Period as Compared to Baseline for Participants With Respiratory Decline on Standard Treatment — 0; 0; 0; 1…